Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

NCT04064242 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Sarcoidosis

Interventions

DRUG: CMK389
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals